Sophia Genetics SA (SOPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sophia Genetics SA (SOPH) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.79 Million) by net assets ($60.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SOPH defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Sophia Genetics SA - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sophia Genetics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sophia Genetics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sophia Genetics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sky Harbour Group Corporation
NYSE:SKYH
|
-0.024x |
|
Denny’s Corp
NASDAQ:DENN
|
-0.489x |
|
Advancetek Enterprise Co Ltd
TW:1442
|
-0.034x |
|
Jindal Worldwide Limited
NSE:JINDWORLD
|
0.100x |
|
Beijing New Universal Science and Technology Co Ltd
SHE:300472
|
0.155x |
|
PI Advanced Materials Co. Ltd
KQ:178920
|
0.051x |
|
Zorlu Enerji Elektrik Uretim AS
IS:ZOREN
|
-0.033x |
|
Abeona Therapeutics Inc
NASDAQ:ABEO
|
-0.113x |
Annual Cash Flow Conversion Efficiency for Sophia Genetics SA (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sophia Genetics SA from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SOPH stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $96.49 Million | $-42.82 Million | -0.444x | -38.36% |
| 2023-12-31 | $151.44 Million | $-48.58 Million | -0.321x | +8.42% |
| 2022-12-31 | $200.13 Million | $-70.09 Million | -0.350x | -66.48% |
| 2021-12-31 | $275.40 Million | $-57.94 Million | -0.210x | +33.36% |
| 2020-12-31 | $100.51 Million | $-31.73 Million | -0.316x | +77.82% |
| 2019-12-31 | $22.25 Million | $-31.68 Million | -1.424x | -- |
About Sophia Genetics SA
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutic… Read more